Candel Therapeutics, Inc. (NASDAQ:CADL) Given Average Rating of “Moderate Buy” by Brokerages

Candel Therapeutics, Inc. (NASDAQ:CADL) has been given an average recommendation of “Moderate Buy” by the nine research firms that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and six have issued a buy recommendation on the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $18.00.

Several analysts have commented on CADL shares. Canaccord Genuity Group reissued a “buy” rating and set a $25.00 price target on shares of Candel Therapeutics in a research report on Friday, March 13th. Zacks Research raised shares of Candel Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Friday, May 15th. Citigroup decreased their price target on shares of Candel Therapeutics from $24.00 to $22.00 and set a “buy” rating for the company in a research report on Friday, March 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Candel Therapeutics in a research report on Monday, April 20th. Finally, Wall Street Zen upgraded shares of Candel Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, June 1st.

Hedge Funds Weigh In On Candel Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. BNP Paribas Financial Markets boosted its position in Candel Therapeutics by 128.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 7,901 shares of the company’s stock worth $40,000 after purchasing an additional 4,439 shares in the last quarter. China Universal Asset Management Co. Ltd. purchased a new position in Candel Therapeutics in the 4th quarter valued at $51,000. Tower Research Capital LLC TRC lifted its holdings in Candel Therapeutics by 361.7% in the 2nd quarter. Tower Research Capital LLC TRC now owns 9,608 shares of the company’s stock valued at $49,000 after purchasing an additional 7,527 shares in the last quarter. Invesco Ltd. purchased a new position in Candel Therapeutics in the 1st quarter valued at $59,000. Finally, ProShare Advisors LLC acquired a new stake in shares of Candel Therapeutics in the 4th quarter worth $59,000. Institutional investors and hedge funds own 13.93% of the company’s stock.

Candel Therapeutics Stock Performance

CADL stock opened at $8.51 on Monday. The firm has a market cap of $623.53 million, a price-to-earnings ratio of -8.68 and a beta of -0.49. The firm has a 50-day simple moving average of $6.88 and a two-hundred day simple moving average of $5.95. Candel Therapeutics has a one year low of $4.35 and a one year high of $9.57. The company has a debt-to-equity ratio of 0.34, a quick ratio of 28.05 and a current ratio of 28.05.

Candel Therapeutics (NASDAQ:CADL) last released its quarterly earnings results on Thursday, May 14th. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.16. On average, equities analysts forecast that Candel Therapeutics will post -0.97 EPS for the current fiscal year.

About Candel Therapeutics

Candel Therapeutics (NASDAQ:CADL) is a clinical-stage immuno-oncology company focused on the development of next-generation oncolytic viral therapies designed to treat solid tumors. The company’s lead candidate, CAN-2409, is a locally administered, gene-delivered viral therapy engineered to selectively replicate in cancer cells and induce immunogenic cell death. Candel leverages proprietary virus engineering platforms to enhance tumor-specific replication and stimulate anti-tumor immune responses, aiming to improve outcomes for patients with high unmet medical needs.

In addition to its lead program, Candel’s pipeline includes CAN-3110, an oncolytic herpes simplex virus targeting recurrent high-grade glioma, and other novel viral constructs being explored for a variety of solid tumor indications.